Related Experiment Video
Updated: Jun 16, 2025

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
Published on: April 25, 2025
Otolith function in Usher type II syndrome
Ana Margarida Amorim1,2, Diliana Rebelo1, Ana Beatriz Ramada1
1Otorhinolaringology Department, Coimbra Local Health Unit, EPE, Coimbra, Portugal.
Otolith dysfunction is present in Usher syndrome type II (USH2), impacting balance and potentially vision. Vestibular evoked myogenic potentials (VEMPs) reveal abnormalities in USH2 patients, suggesting a need for their inclusion in clinical evaluations.
Area of Science:
- Otolaryngology
- Neuroscience
- Genetics
Background:
- Usher syndrome type II (USH2) is a genetic disorder causing hearing and vision loss, with previously assumed intact vestibular function.
- Emerging evidence suggests otolith vestibular receptors may be involved in USH2 pathophysiology.
Purpose of the Study:
- To evaluate the dynamic function of otolith vestibular receptors in individuals with Usher syndrome type II.
- To correlate vestibular function test results with patient-reported outcomes for balance and dizziness.
Main Methods:
- Twenty-two USH2 patients and age-matched controls underwent comprehensive vestibular testing, including cervical and ocular vestibular evoked myogenic potentials (c-VEMPs and o-VEMPs).
- Vestibular test results were analyzed alongside scores from the Activities Balance Scale (ABC) and Dizziness Handicap Inventory (DHI).
Main Results:
- Absence of c-VEMPs was noted in 15 USH2 patients compared to 4 controls (p=0.034).
- Significant differences in o-VEMP N1 latencies, N1-P1 amplitudes, and asymmetry ratios were observed between USH2 patients and controls (p<0.010, p<0.003, p<0.014, respectively).
- A strong correlation was found between o-VEMP amplitude and DHI scores in USH2 patients (p=0.003).
Conclusions:
- The study indicates the presence of otolith dysfunction in Usher syndrome type II, independent of subjective dizziness.
- Integrating vestibular evoked myogenic potential testing into the clinical assessment of USH2 patients can improve disease characterization and management.
Related Concept Videos
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Ultrasonography
During an ultrasonography procedure, a handheld device called...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Equilibrium and Balance
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

